Dec 28, 2007 by Brian LawlerInvestors Wary on Noven ApprovalThe "tentative" status may be making investors jittery.
Dec 27, 2007 by Brian LawlerBreaking Down a Biotech's AssetsA hedge fund thinks Enzon's shares are undervalued, and here's why.
Dec 26, 2007 by Brian LawlerExelixis Awaits Bristol-Myers DecisionRejection might not mean the end of the road for this cancer treatment.
Dec 21, 2007 by Brian LawlerTrial and Error for Array BioPharmaIts unique compound to fight the growth of cancer cells fails in trials.
Dec 19, 2007 by Brian LawlerNovartis' Diabetes Battle Can BeginNovartis gets set to market a novel diabetes treatment, with EU approval that is not all it had hoped for.
Dec 18, 2007 by Brian LawlerThe Final Nail in Neurochem's CoffinThe European Union rejects Neurochem's lead drug.
Dec 18, 2007 by Brian LawlerPDL Liquidation Sale BeginsIts sale of a chemotherapy drug indicates it could recoup what it paid for its ESP assets.
Dec 18, 2007 by Brian LawlerCervarix Won't Save Glaxo YetThe FDA has another delay for this HPV vaccine.
Dec 17, 2007 by Brian LawlerGlaxo, Exelixis Trade GiftsThe former will take over development of the latter's drug.
Dec 17, 2007 by Brian LawlerIs There Value in This Hypertension Fighter?Encysive releases sales guidance for its lead drug.
Dec 14, 2007 by Brian LawlerIgnore the Dendreon HooplaProvenge should have no problems despite the recent disclosure problems.
Dec 14, 2007 by Brian LawlerFDA Knocks Neurocrine a Knuckle SandwichThe FDA clobbers the drugmaker with another delay.
Dec 13, 2007 by Brian LawlerSo-So Results From PanacosInvestors are discouraged after it releases the latest data for its top drug.
Dec 13, 2007 by Brian LawlerArray BioPharma Has No Problem Finding PartnersCEO Robert Conway reveals Array's edge for finding partners and cruising the competitive landscape.
Dec 13, 2007 by Brian LawlerAlpharma Gives to GetThe generics drugmaker forecasts its 2008 financials.
